Skin Cancer & Melanoma

Latest News

Data from RELATIVITY-047 show consistent benefits with nivolumab/relatlimab across most patient subgroups, including those with BRAF-mutated disease.
Nivolumab/Relatlimab Shows Sustained Efficacy in Advanced Melanoma

February 15th 2025

Data from RELATIVITY-047 show consistent benefits with nivolumab/relatlimab across most patient subgroups, including those with BRAF-mutated disease.

RP1/Nivolumab Earns Priority Review in Anti–PD-1 Failed Advanced Melanoma
RP1/Nivolumab Earns Priority Review in Anti–PD-1 Failed Advanced Melanoma

January 21st 2025

Investigators of the phase 3 C-POST trial will continue to follow up with patients and assess the key secondary end point of overall survival.
Adjuvant Cemiplimab Boosts DFS in Cutaneous Squamous Cell Carcinoma

January 13th 2025

Cosibelimab has been approved by the FDA as a treatment for patients with cutaneous squamous cell carcinoma.
FDA Approves Cosibelimab in Cutaneous Squamous Cell Carcinoma

December 13th 2024

Vusolimogene oderparepvec in combination with nivolumab has received breakthrough therapy designation from the FDA in advanced melanoma.
FDA Assigns BTD and Receives BLA for RP1 Combo in Advanced Melanoma

November 22nd 2024

Latest CME Events & Activities

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

View More

<1
...
2425262728